Chemours (CC)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$15.30-1.16%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · CC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $15 CC trades at 21× p/e, in line with its 18× p/e peer median — but our blended $21 fair value sits well above the price. It's a high-confidence read. Analysts target $17–$30. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $21.00 | — | — | Analyst | high |
| Peer EV/EBITDA | 12M | $7.43 | 12.3 | 2.36 | TTM | high |
| Peer P/FCF | 12M | $21.45 | 26.0 | 0.83 | TTM | high |
| Peer P/E | 12M | $25.48 | 15.6 | 1.63 | ntm analyst | high |
| Peer P/S |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$17.00 – $30.00 (median $21.00) · 9 analysts · as of 2026-08-13
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2025-Q4, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $57.17 |
| 1.5 |
| 38.33 |
| TTM |
| high |
| triangulated | 12M | $12.93 | 17.9 | 0.72 | Triangulated | high |
| Peer P/FCF | 3Y | $23.32 | 26.0 | 0.90 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $24.65 | 26.0 | 0.95 | Hist. CAGR(prov.) | medium |